Detail Data
Volume (24h): 4,626,503 shares
P/E Ratio: /
Forward P/E: -5.52
EPS: -4.5 USD
Forward EPS: -4.77 USD
Number of Shares: 101,162,026 shares
Market Capitalization: 2,662,584,320.00 USD

Dividend

Dividend Value
Dividend Amount According to our data, the company Beam Therapeutics does not currently pay dividends.
Annual Yield %: -
Ex-dividend Date: -
5-Year Avg Yield %: -
Payout Ratio: -
Last Dividend Value: -
Last Dividend Date: -

Analyst Forecast

Most analysts have issued a strong_buy recommendation for Beam Therapeutics stock. The current number of analysts covering this company is 13. The highest target price is 80 USD, while the lowest target price is 20 USD. The median target valuation set by analysts is 43 USD. These forecasts and recommendations provide insight into how analysts view the future stock performance of Beam Therapeutics.
Analysts Recommendation
Issued Recommendation: According to our data, the recommendation for Beam Therapeutics stock is: strong_buy
Number of Analysts: 13
Highest Target Price: 80 USD
Lowest Target Price: 20 USD
Median Target Price: 43 USD

Fundamental Indicators

Indicator Data
Total Revenue: 60,272,000.00 USD
Net Income: -398,583,008.00 USD
Price-to-Book (P/B): 2.46
PEG Ratio: /
Exchange: NasdaqGS
Industry: Biotechnology
Sector: Healthcare
Number of Employees: 509
Country: United States

Where to Buy Beam Therapeutics Stock?

You can purchase Beam Therapeutics stock on the NasdaqGS under the ticker symbol: BEAM. Several stock brokers or banks offer trading services for these stocks. Popular stock brokers like XTB and eToro allow you to buy real stocks and ETFs with zero or minimal commissions. Banks usually charge higher fees. Remember, investing in stocks involves risks, so it's important to carefully consider your financial situation and investment goals.

1

Real stocks and ETFs. Low minimum deposit, only 50 EUR. Option to copy trades. Advanced stock analysis and free education.

Trustpilot rating 4.4/5 Google play rating 4.2/5
Invest in Stocks with eToro
★★★★★ 5.0
2

Real stocks and ETFs + free demo account. Low fees + fast customer support. More than 5,200 instruments available for trading. Free training and education. Regular live streams on YouTube.

Trustpilot rating 3.6/5 Google play rating 4.5/5
Try Free Demo Account
★★★★☆ 4.8
Risk warning: Trading CFDs involves a high risk of financial loss. Between 51%-eToro -89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

More Information on Beam Therapeutics Stock

Indicator Value
Company Revenue: 60,272,000.00 USD
EBITDA: -423,993,984.00 USD - Negative EBITDA may signal financial challenges or growth investments.
Earnings Per Share: -4.5 USD
Book Value Per Share: 10.70 USD
Total Cash: 1,150,337,024.00 USD
Total Cash per Share: 11.71 USD
Total Debt: 154,803,008.00 USD
Debt to Equity Ratio: 0.15
Quick Ratio 6.61
Current Ratio 6.75
Free Cash Flow -164,037,248.00 USD
Operating Cash Flow -344,824,000.00 USD
Gross Margins -
EBITDA Margins -
Operating Margins -1,419.22 %
Profit Margins -
Return on Assets -21.0 %
Return on Equity -41.9 %
Earnings Growth (1 year) -
Revenue Growth (1 year) -28.1 %
Quarterly Earnings Year-over-Year Growth -
Market Capitalization 2,662,584,320.00 USD
Enterprise Value 1,591,109,120.00 USD
EV/Revenue 26.399
EV/EBITDA -3.753
Float Shares 87,651,036 shares
Shares Outstanding 101,162,026 shares
Held Percent Insiders 0.01 %
Held Percent Institutions 105.07 %
Shares Short 21,380,736
Shares Short Prior Month 25,477,842
Date Short Interest 2025-09-30
Short Percentage of Total Shares 21.14 %
Short Ratio 7.13
Beta 2.25
Short Percentage of Float 23.75 %
Implied Shares Outstanding 101,162,026

Frequently Asked Questions (FAQ)

According to our data, the company Beam Therapeutics does not pay dividends yet, even in 2025.

Beam Therapeutics shares are traded on the NasdaqGS stock exchange under the ticker: BEAM. You can buy or trade them through a variety of stock brokers who provide real stock trading services.

According to our data, the recommendation for Beam Therapeutics shares is from a total of 13 analysts. The average target price prediction is 43 USD per share.

The total number of Beam Therapeutics shares on the exchange is 101,162,026.00 shares, which at the current market capitalization gives the company a total valuation of 2,662,584,320.00 USD.